Skip to main content

Koninklijke Philips N.V. (PHIA.AS)

Euronext Amsterdam Healthcare Medical - DevicesView data quality →
52.0Fair

ValueMarkers Composite Index

Top 41%#26,574 of 44,707
Undervalued

49% below intrinsic value ($56)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.80
Low Risk
Altman
2.03
Grey Zone
DCF Value
$56
Undervalued
ROIC
5.7%
Low
P/E
25.6
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Koninklijke Philips N.V. (PHIA.AS) — VMCI valuation read

Koninklijke Philips N.V. (PHIA.AS) carries a VMCI composite of 52/100, 2 points above the Healthcare sector median of 50. Among mid-cap names, that gap places PHIA.AS in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The PHIA.AS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads PHIA.AS trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.5x is the binding constraint on the bear case, the line to track on Koninklijke Philips N.V.'s next 10-Q.

PHIA.AS fell 1.2% over the trailing 7 days, with a -23.7% read on a 30-day basis.

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

CEO: Roy W. O. Jakobs67,247 employeesNLwww.philips.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PHIA.AS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.